Results 131 to 140 of about 72,161 (311)
Journal of Clinical Endocrinology and Metabolism, 2019 CONTEXT The gut-derived incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) have been suggested to play a role in bone metabolism.
N. Bergmann +9 more
semanticscholar +1 more source
Diabetes, Obesity and Metabolism, EarlyView.Abstract Aim Eloralintide (LY3841136) is a potent, long‐acting selective amylin receptor agonist currently under development for the treatment of obesity with once‐weekly subcutaneous dosing. Materials and Methods This 12‐week Phase 1, randomised, placebo‐controlled, participant‐ and investigator‐blinded, multiple ascending dose study evaluated the ...
Shobha Bhattachar +8 more
wiley +1 more source
GIP and GLP-1: Stepsiblings Rather Than Monozygotic Twins Within the Incretin Family
Diabetes, 2019 The importance of the incretin effect for the postprandial augmentation of insulin released has long been recognized (1). However, there has been a long-standing controversy as to the relative importance of the various gastrointestinal hormones in ...
M. Nauck, J. Meier
semanticscholar +1 more source
Diabetes, Obesity and Metabolism, EarlyView.Abstract Aims This study aims to compare the risk of major adverse cardiovascular events (MACE) among United States individuals with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD) treated with once‐weekly semaglutide vs. dulaglutide.
Xi Tan +7 more
wiley +1 more source
Dual action of imeglimin on insulin secretion and sensitivity in type 2 diabetes
Diabetes, Obesity and Metabolism, EarlyView.Abstract Aims Imeglimin is a novel oral hypoglycemic agent approved for the treatment of type 2 diabetes in Japan, with dual actions to enhance insulin secretion and improve insulin sensitivity, suggested by preclinical evidence. However, the effect of imeglimin on tissue‐specific insulin sensitivity and glucose kinetics using glucose tracers is ...
Tsubasa Tajima +10 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.Abstract Aims Obesity is a growing global health crisis; pharmacotherapies such as tirzepatide combined with multidisciplinary lifestyle support have shown promise but real‐world evidence in digital weight‐loss services (DWLSs) is limited. This retrospective study evaluated 6‐ and 12‐month weight loss, adherence and predictors of outcomes in an ...
Louis Talay +3 more
wiley +1 more source
Journal of Lipid Research, 2010 GIP (glucose-dependent insulinotropic polypeptide) is a gastrointestinal hormone that regulates pancreatic islet function. Additionally, emerging evidence suggests an important physiological role for GIP in the regulation of adipocyte metabolism.
Su-Jin Kim +2 more
doaj +1 more source
Diffractive production of dijets by double Pomeron exchange processes
, 2003 A phenomenological description of diffractive dijet hadroproduction via double Pomeron exchange is presented. This description is based on a modified version of the Ingelman-Schlein model which includes the evolution of the Pomeron structure function and
A. A. Natale +29 more
core +1 more source
Diabetes, Obesity and Metabolism, EarlyView.Abstract Aims Once‐weekly (OW) insulins represent a promising strategy to reduce injection burden and improve adherence in type 2 diabetes management. This meta‐analysis aimed to quantify pooled effect sizes for key biological and clinical outcomes, integrating new findings from the five large trials published in 2025.
Olivier Bourron, Damien Denimal
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.Abstract Aims As type 2 diabetes (T2D) continues to rise globally and remains a major driver of cardiovascular disease, its remission has emerged as a therapeutic target. Current evidence supports bariatric surgery and low‐calorie diets with meal replacements.
Brighid McKay +19 more
wiley +1 more source